UB Paderborn / Katalog / Suche / in CDI

Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway

Journal of headache and pain, 2020-08, Vol.21 (1), p.99-99, Article 99

2020

Link zum Volltext

Verfügbarkeit prüfen

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

Lancet neurology, 2011-12, Vol.10 (12), p.1049-1057

2011

Link zum Volltext

Verfügbarkeit prüfen

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence

Annual review of pharmacology and toxicology, 2001-01, Vol.41 (1), p.237-260

2001

Link zum Volltext

Verfügbarkeit prüfen

A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers

Pharmacology research & perspectives, 2021-05, Vol.9 (3), p.e00792-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

Altered pattern of brain dopamine synthesis in male adolescents with attention deficit hyperactivity disorder

Behavioral and brain functions, 2006-12, Vol.2 (1), p.40-40

2006

Link zum Volltext

Verfügbarkeit prüfen

NMDA‐Receptor Activity Visualized with (S)‐[N‐Methyl‐11C]Ketamine and Positron Emission Tomography in Patients with Medial Temporal Lobe Epilepsy

Epilepsia (Copenhagen), 1999-01, Vol.40 (1), p.30-37

1999

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia

Movement disorders, 2020-06, Vol.35 (6), p.1046-1054

2020

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

Movement disorders, 2013-09, Vol.28 (10), p.1407-1415

Anon

2013

Link zum Volltext

Verfügbarkeit prüfen

Extrastriatal dopamine D 2 receptor binding in Huntington's disease

Human brain mapping, 2011-10, Vol.32 (10), p.1626-1636

2011

Link zum Volltext

Verfügbarkeit prüfen

First‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers

Clinical pharmacology in drug development, 2021-12, Vol.10 (12), p.1485-1494

2021

Link zum Volltext

Verfügbarkeit prüfen

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease

Journal of Huntington's disease, 2018-01, Vol.7 (1), p.1

2018

Link zum Volltext

Verfügbarkeit prüfen

The dopaminergic stabilizer pridopidine decreases expression of l-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model

European journal of pharmacology, 2013-01, Vol.698 (1-3), p.278-285

2013

Link zum Volltext

Verfügbarkeit prüfen

Reversible chorea in primary antiphospholipid syndrome

Movement disorders, 1998-01, Vol.13 (1), p.147-149

1998

Link zum Volltext

Verfügbarkeit prüfen

Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial

NPJ Parkinson's Disease, 2018, Vol.4 (1), p.35-5, Article 35

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease

Clinical neuropharmacology, 2010-09, Vol.33 (5), p.260-264

2010

Link zum Volltext

Verfügbarkeit prüfen

Extrastriatal dopamine D2 receptor binding in Huntington's disease

Human brain mapping, 2011-10, Vol.32 (10), p.1626-1636

2011

Link zum Volltext

Verfügbarkeit prüfen

Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease

Clinical neuropharmacology, 2011-05, Vol.34 (3), p.95-100

2011

Link zum Volltext

Verfügbarkeit prüfen

Extrastriatal dopamine D(2) receptor binding in Huntington's disease

Human brain mapping, 2011-10, Vol.32 (10), p.1626

2011

Link zum Volltext

Verfügbarkeit prüfen

Validation of the first quality-of-life measurement for patients with Huntington's disease: the Huntington Quality of Life Instrument

International clinical psychopharmacology, 2012-07, Vol.27 (4), p.208

2012

Link zum Volltext

Verfügbarkeit prüfen

Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease

Journal of Huntington's disease, 2015-01, Vol.4 (2), p.131

2015

Link zum Volltext

Verfügbarkeit prüfen

A Comparison of 11C-Labeled l-DOPA and l-Fluorodopa as Positron Emission Tomography Tracers for the Presynaptic Dopaminergic System

Journal of cerebral blood flow and metabolism, 1999-10, Vol.19 (10), p.1142-1149

1999

Link zum Volltext

Verfügbarkeit prüfen

Liquid chromatographic analysis of brain homogenates and microdialysates for the quantification of l-[β- 11C]DOPA and its metabolites for the validation of positron emission tomography studies

Journal of pharmaceutical and biomedical analysis, 1995-04, Vol.13 (4), p.361-367

1995

Link zum Volltext

Verfügbarkeit prüfen

Dopamine autoreceptor function is lost in advanced Parkinson's disease

Neurology, 1999-01, Vol.52 (1), p.120

1999

Link zum Volltext

Verfügbarkeit prüfen

Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease

Annals of neurology, 1997-03, Vol.41 (3), p.334-340

1997

Link zum Volltext

Verfügbarkeit prüfen

A Comparison of C-Labeled L-DOPA and L-Fluorodopa as Positron Emission Tomography Tracers for the Presynaptic Dopaminergic System

Journal of cerebral blood flow and metabolism, 1999-10, Vol.19 (10), p.1142-1149

1999

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence

A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers

Altered pattern of brain dopamine synthesis in male adolescents with attention deficit hyperactivity disorder

NMDA‐Receptor Activity Visualized with (S)‐[N‐Methyl‐11C]Ketamine and Positron Emission Tomography in Patients with Medial Temporal Lobe Epilepsy

A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

Extrastriatal dopamine D 2 receptor binding in Huntington's disease

First‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers

Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease

The dopaminergic stabilizer pridopidine decreases expression of l-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model

Reversible chorea in primary antiphospholipid syndrome

Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial

Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease

Extrastriatal dopamine D2 receptor binding in Huntington's disease

Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease

Extrastriatal dopamine D(2) receptor binding in Huntington's disease

Validation of the first quality-of-life measurement for patients with Huntington's disease: the Huntington Quality of Life Instrument

Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease

A Comparison of 11C-Labeled l-DOPA and l-Fluorodopa as Positron Emission Tomography Tracers for the Presynaptic Dopaminergic System

Liquid chromatographic analysis of brain homogenates and microdialysates for the quantification of l-[β- 11C]DOPA and its metabolites for the validation of positron emission tomography studies

Dopamine autoreceptor function is lost in advanced Parkinson's disease

Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease

A Comparison of C-Labeled L-DOPA and L-Fluorodopa as Positron Emission Tomography Tracers for the Presynaptic Dopaminergic System

Suchergebnisse filtern